- Home
- MNOV vs GNLX Comparison
MNOV vs GNLX Comparison
Compare MNOV & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- GNLX
- Stock Information
- Founded
- MNOV 2000
- GNLX 2001
- Country
- MNOV United States
- GNLX United States
- Employees
- MNOV N/A
- GNLX N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- GNLX Health Care
- Exchange
- MNOV Nasdaq
- GNLX Nasdaq
- Market Cap
- MNOV 65.7M
- GNLX 128.0M
- IPO Year
- MNOV 2005
- GNLX 2023
- Fundamental
- Price
- MNOV $1.23
- GNLX $3.93
- Analyst Decision
- MNOV Strong Buy
- GNLX Strong Buy
- Analyst Count
- MNOV 2
- GNLX 4
- Target Price
- MNOV $7.00
- GNLX $17.75
- AVG Volume (30 Days)
- MNOV 64.6K
- GNLX 147.7K
- Earning Date
- MNOV 11-12-2025
- GNLX 11-13-2025
- Dividend Yield
- MNOV N/A
- GNLX N/A
- EPS Growth
- MNOV N/A
- GNLX N/A
- EPS
- MNOV N/A
- GNLX N/A
- Revenue
- MNOV $134,599.00
- GNLX N/A
- Revenue This Year
- MNOV N/A
- GNLX N/A
- Revenue Next Year
- MNOV N/A
- GNLX N/A
- P/E Ratio
- MNOV N/A
- GNLX N/A
- Revenue Growth
- MNOV N/A
- GNLX N/A
- 52 Week Low
- MNOV $1.13
- GNLX $1.95
- 52 Week High
- MNOV $2.55
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- MNOV 39.02
- GNLX 60.25
- Support Level
- MNOV $1.22
- GNLX $3.76
- Resistance Level
- MNOV $1.38
- GNLX $3.61
- Average True Range (ATR)
- MNOV 0.04
- GNLX 0.25
- MACD
- MNOV -0.01
- GNLX 0.05
- Stochastic Oscillator
- MNOV 5.88
- GNLX 69.23
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.